KR950023402A - Pharmaceutical compositions with synergistic effect - Google Patents

Pharmaceutical compositions with synergistic effect Download PDF

Info

Publication number
KR950023402A
KR950023402A KR1019940000246A KR19940000246A KR950023402A KR 950023402 A KR950023402 A KR 950023402A KR 1019940000246 A KR1019940000246 A KR 1019940000246A KR 19940000246 A KR19940000246 A KR 19940000246A KR 950023402 A KR950023402 A KR 950023402A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight ratio
analgesic
capsaicin compound
nonsteroidal
Prior art date
Application number
KR1019940000246A
Other languages
Korean (ko)
Other versions
KR100315184B1 (en
Inventor
이상섭
김원배
김순희
배은주
Original Assignee
유충식
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유충식, 동아제약 주식회사 filed Critical 유충식
Priority to KR1019940000246A priority Critical patent/KR100315184B1/en
Publication of KR950023402A publication Critical patent/KR950023402A/en
Application granted granted Critical
Publication of KR100315184B1 publication Critical patent/KR100315184B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 다음 일반식(I)의 화합물The present invention is a compound of formula (I)

(식에서 R1, R2, R3은 각각 수소원자, 알킬기 또는 알콕시기를 나타내며, n은 1 대지 5의 정수이다.) 및 N-(4-하이드록시벤질)-9Z-옥타데켄아미드, 1-(4-하이드록시-3-메톡시페닐)-3-데칸온, 1-(4-하이드록시-3-메톡시페닐)-도덱-4-엔-3-온에서 선택된 캅사이신류 화합물 및 비스테로이드성 진통제류에서 선택된 진통제와의 혼합 조성물에 관한 것로, 이를 투여함으로써 부작용은 심화되지 않고 진통효과가 상승되는 복합 조성물을 제공하는 것이다.(Wherein R 1 , R 2 , R 3 each represent a hydrogen atom, an alkyl group or an alkoxy group, n is an integer of 1 to 5) and N- (4-hydroxybenzyl) -9Z-octadekenamide, 1- Capsaicin compounds and nonsteroids selected from (4-hydroxy-3-methoxyphenyl) -3-decanone, 1- (4-hydroxy-3-methoxyphenyl) -dodec-4-en-3-one The present invention relates to a mixed composition with analgesic agents selected from sexual analgesics, and by administering the same, it provides a composite composition in which analgesic effects are enhanced without increasing the side effects.

Description

진통효과 상승작용을 갖는 약학적 조성물Pharmaceutical compositions with synergistic effect

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (22)

1-(4-하이드록시-3-메톡시페닐)-3-데칸온, N-(4-하이드록시벤질)-9Z-옥타데켄아미드, 1-(4-하이드록시-3-메톡시페닐)-도덱-4-엔-3-온에서 선택된 캅사이신류 화합물 및 비스테로이드성 진통제를 중량비 20:1 내지 1:20으로 함유하며, 약제학적으로 허용되는 담체로 이루어지는 약학적 조성물.1- (4-hydroxy-3-methoxyphenyl) -3-decanone, N- (4-hydroxybenzyl) -9Z-octadekenamide, 1- (4-hydroxy-3-methoxyphenyl) A pharmaceutical composition comprising a capsaicin compound selected from dodec-4-en-3-one and a nonsteroidal analgesic agent in a weight ratio of 20: 1 to 1:20, and comprising a pharmaceutically acceptable carrier. 제1항에 있어서, 중량비가 10:1에서 1:10까지인 약학적 조성물.The pharmaceutical composition of claim 1, wherein the weight ratio is from 10: 1 to 1:10. 제1항에 있어서, 비스테로이드성 진통제가 살리실레이트류 진통제, 이부프로펜, 나프록센, 케토프로펜, 페노프로펜, 수프로펜, 플루르비프로펜, 베녹사프로펜 및 그들의 약제학적으로 허용되는 염류 중에서 선택됨을 특징으로 하는 약학적 조성물.A non-steroidal analgesic drug according to claim 1 is a salicylate analgesic agent, ibuprofen, naproxen, ketoprofen, phenopropene, suprofen, flurbiprofen, benoxapropene and their pharmaceutically acceptable Pharmaceutical composition, characterized in that selected from among the salts. 제1항에 있어서, 비스테로이드성 진통제가 아스피린인 약학적 조성뭍.The pharmaceutical composition of claim 1, wherein the nonsteroidal analgesic is aspirin. 제1항에 있어서, 캅사이신류 화합물과 아스피린의 중량비가 3:1에서 1:13까지인 약학적 조성물.The pharmaceutical composition according to claim 1, wherein the weight ratio of the capsaicin compound to aspirin is from 3: 1 to 1:13. 제1항에 있어서. 비스테로이드성 진통제가 이부프로펜인 약학적 조성물.The method of claim 1. Pharmaceutical composition wherein the nonsteroidal analgesic is ibuprofen. 제1항에 있어서, 캅사이신류 화합물과 이부프로펜의 중량비가 5:1에서 1:5까지인 약학적 조성물.The pharmaceutical composition of claim 1, wherein the weight ratio of the capsaicin compound to ibuprofen is from 5: 1 to 1: 5. 다음 일반식(I)의 캅사이신류 화합물 및 비스테로이드성 진통제를 1:1000에서 1:1의 중량비로 함유하며, 약제학적으로 허용되는 담체로 이루어지는 약학적 조성물.A pharmaceutical composition comprising a capsaicin compound of formula (I) and a nonsteroidal analgesic agent in a weight ratio of 1: 1000 to 1: 1, comprising a pharmaceutically acceptable carrier. 식에서, R1, R2, R3은 각각 수소원자, 알킬기 또는 알콕시기를 나타내며, n은 1 내지 5의 정수이다.In formula, R <1> , R <2> , R <3> represents a hydrogen atom, an alkyl group, or an alkoxy group, respectively, and n is an integer of 1-5. 제8항에 있어서, 중량비가 1:500에서 1:1까지인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the weight ratio is from 1: 500 to 1: 1. 제8항에있어서, 비스테로이드성 진통제가 살리실레이트, 살리실레이트-유사진통해열제, 살리실레이트-유사 소염진통제, 이부프로펜, 나프록센, 케토프로펜, 페노프로펜, 수프로펜, 플루르비프로펜, 베녹사프로펜, 파이록시캄, 테녹시캄 및 이들의 약제학적으로 허용가능한 염류중에서 선택됨을 특징으로 하는 약학적 조성물.9. The nonsteroidal analgesic according to claim 8, wherein the nonsteroidal analgesic is salicylate, salicylate-like antipyretic, salicylate-like anti-inflammatory, ibuprofen, naproxen, ketoprofen, phenopropene, suprofen, flu A pharmaceutical composition, characterized in that it is selected from bipropene, venoxapropene, pyloxycam, tenoxycam and their pharmaceutically acceptable salts. 제8항에 있어서, 비스테로이드성 진통제가 아스피린인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the nonsteroidal analgesic is aspirin. 제8항에 있어서, 캅사이신류 화합물과 비스테로이드성 진통제의 중량비가 1:200에서 1:1까지인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the weight ratio of the capsaicin compound to the nonsteroidal analgesic agent is from 1: 200 to 1: 1. 제8항에있어서, 캅사이신류 화합물이 N-[3-(3,4-비에틸페닐)프로필]-4-(2-아미노에톡시)-3-메톡시페닐아세트아미드인 약학적 조성물.The pharmaceutical composition according to claim 8, wherein the capsaicin compound is N- [3- (3,4-biethylphenyl) propyl] -4- (2-aminoethoxy) -3-methoxyphenylacetamide. 제8항에 있어서, N-[3-(3,4-비에틸페닐)프로필]-4-(2-아미노에톡시)-3-메톡시페닐아세트아미드와 아스피린의 중량비가 1:100에서 1:1까지인 약학적 조성물.The weight ratio of N- [3- (3,4-biethylphenyl) propyl] -4- (2-aminoethoxy) -3-methoxyphenylacetamide to aspirin is in the range of 1: 100 to 1 Pharmaceutical compositions up to: 1. 제8항에 있어서, 비스테로이드성 진통제가 이부프로펜인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the nonsteroidal analgesic is ibuprofen. 제8항에 있어서, 캅사이신류 화합물과 이부프로펜의 중량비가 1:100에서 1:1까지인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the weight ratio of the capsaicin compound to ibuprofen is from 1: 100 to 1: 1. 제16항에 있어서, 캅사이신류 화합물이 N-[3-(3,4-비메틸페닐)프로필]-4-(2-아미노에톡시)-3-메톡시페아세트아미드인 약학적 조성물.The pharmaceutical composition according to claim 16, wherein the capsaicin compound is N- [3- (3,4-bimethylphenyl) propyl] -4- (2-aminoethoxy) -3-methoxyfeacetamide. 제8항에 있어서, 비스테로이드성 진통제가 살리실레이트-유사 진통해열제 또는 그의 약제학적으로 허용가능한 염류인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the nonsteroidal analgesic is a salicylate-like analgesic or a pharmaceutically acceptable salt thereof. 제8항에 있어서, 비스테로이드성 진통제가 아세트아미노펜인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the nonsteroidal analgesic is acetaminophen. 제8항에 있어서, 캅사이신류 화합물과 아세트아미노펜의 중량비가 1:1000에서 1:1까지인 약학적 조성물.The pharmaceutical composition of claim 8, wherein the weight ratio of the capsaicin compound to acetaminophen is from 1: 1000 to 1: 1. 제8항에 있어서, 비스테로이드성 진통제가 테녹시캄인 약학적-조성물.The pharmaceutical-composition of claim 8, wherein the nonsteroidal analgesic is tenoxycam. 제8항에 있어서, 캅사이신류 화합물과 테녹시캄의 중량비가 1:5에서 1:1까지인 약학적 조성물.The pharmaceutical composition according to claim 8, wherein the weight ratio of the capsaicin compound and tenoxycam is from 1: 5 to 1: 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940000246A 1994-01-08 1994-01-08 Pharmaceutical composition having increased analgesic effect KR100315184B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940000246A KR100315184B1 (en) 1994-01-08 1994-01-08 Pharmaceutical composition having increased analgesic effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940000246A KR100315184B1 (en) 1994-01-08 1994-01-08 Pharmaceutical composition having increased analgesic effect

Publications (2)

Publication Number Publication Date
KR950023402A true KR950023402A (en) 1995-08-18
KR100315184B1 KR100315184B1 (en) 2002-02-19

Family

ID=37531553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940000246A KR100315184B1 (en) 1994-01-08 1994-01-08 Pharmaceutical composition having increased analgesic effect

Country Status (1)

Country Link
KR (1) KR100315184B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3091285B2 (en) * 1991-10-14 2000-09-25 ライオン株式会社 External anti-inflammatory analgesic

Also Published As

Publication number Publication date
KR100315184B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
JP2019142964A5 (en)
ES2545076T3 (en) Use of panobinostat HDAC inhibitor for the treatment of myeloma
CO5140109A1 (en) NON-STEROID COMPOUNDS ANTI-INFLAMMATORY DERIVED FROM 2,3- BENZOXAZIN-1-ONA AND FTALIDA AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
KR930007450A (en) Compositions containing tramadol and non-steroidal anti-inflammatory agents
BR9913575A (en) Compositions comprising sympathomimetic amine salts unsuitable for illegal use
KR870003974A (en) Bicyclo substituted phenylacetonitrile derivatives
BRPI0415121A (en) particulate material, solid dosage form, method of manufacturing it, and use of a particulate material or solid dosage form
KR870005973A (en) Derivatives of benzoic acid and benzoic acid esters with anti-inflammatory and analgesic activity
BR9803300A (en) Pharmaceutical formulation.
ATE170845T1 (en) PLATELE AGGREGATION INHIBITORS
KR930009605A (en) Anti-inflammatory or analgesic
BR9507489A (en) Tropano derivatives its preparation and use
DK0622077T3 (en) Angiotensin II antagonists as prophylactic or therapeutic agent for kidney disease
DE69315699D1 (en) INHIBITORS AGAINST AGGREGATION OF BLOOD PLATES
ITMI930582A1 (en) PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
DK0952159T3 (en) Use of phenylhydrazone derivatives as anti-inflammatory or analgesic agents
CO5700738A2 (en) CELECOXIB PROFARMACO
KR950023402A (en) Pharmaceutical compositions with synergistic effect
BR9807330A (en) Agents that inhibit pterygium progress and postoperative recurrence
CO4410322A1 (en) NEW CARBOXAMIDE COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RU2020132293A (en) AMIDE PRODRUGS OF LOW MOLECULAR NUCLEAR RECEPTOR MODULATORS
DK0648202T3 (en) Substituted (arylalkylaminobenzyl) aminopropanamide derivatives, their preparation and use as anti-epileptic, neuroprotective and antidepressant agents
ATE511844T1 (en) ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS CONTAINING CELECOXIB AND IBUPROFEN
WO2005030224A1 (en) Nitrosylated analgesic and/or anti-inflammatory drugs having antiviral activity
JP2008519001A5 (en)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20061218

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee